NIH R01 · 2025
Multivalent mRNA-based malaria vaccines
The heavy burden of Plasmodium falciparum and Plasmodium vivax malaria drove international efforts to coordinate and integrate tools and programs for mosquito vector control, rapid diagnosis, and drug treatment. Success has been significant but may be approaching a limiting boundary. The effort to develop a vaccine to further enhance malaria control has faced many challenges. The advancement of the pre-erythrocytic-stage RTS,S vaccine is a major accomplishment, providing the foundation for an effort that must continue to improve efficacy and durability of vaccine-induced protection to further reduce the disease burden. In this regard, the development of a multivalent vaccine that…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.